Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

PURPOSE: Assess efficacy and toxicity of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, added to, and in maintenance after, concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LA-HNC) and correlate outcomes with EGFR gene copy number alterations. PATIENTS...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Cohen, Ezra E.W., Haraf, Daniel J., Kunnavakkam, Rangesh, Stenson, Kerstin M., Blair, Elizabeth A., Brockstein, Bruce, Lester, Eric P., Salama, Joseph K., Dekker, Allison, Williams, Rosalyn, Witt, Mary Ellyn, Grushko, Tatyana A., Dignam, James J., Lingen, Mark W., Olopade, Olufunmilayo I., Vokes, Everett E.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2010
נושאים:
Original Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903330/
https://ncbi.nlm.nih.gov/pubmed/20498391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.27.0397
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים